Inhibrx Announces Agreement for INBRX-101 outside US, Canada with Chiesi Group

Inhibrx has entered into an agreement with Chiesi Farmaceutici. The agreement grants Chiesi Group an option to exclusively license, develop and commercialize INBRX-101 outside of the United States and Canada effective upon a $10M equity investment in Inhibrx. Inhibrx will retain the rights to develop and commercialize INBRX-101 in the United States and Canada, the largest AATD markets.

INBRX-101 is an Fc-fusion protein based therapeutic candidate expected to enter clinical development in the middle of this year. INBRX-101 is a modified recombinant version of human alpha-1 antitrypsin, or AAT, for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. AATD is a rare genetically defined respiratory disease characterized by progressive destruction of lung tissue. INBRX-101 has the potential to benefit AATD patients with enhanced efficacy and less frequent dosing.

"Chiesi has a strong presence in the European respiratory market, and we look forward to initiating our partnership and working with Chiesi to potentially improve the lives of AATD patients," said Mark Lappe, Chief Executive Officer of Inhibrx.

Register as Visitor to CPhI China 2019 NOW!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.